Higher incidence of delayed methotrexate clearance in pediatric acute lymphoblastic leukemia patients treated with imatinib

Background: Pediatric patients with Philadelphia chromosome positive (Ph+) or ABL-class fusion positive acute lymphoblastic leukemia (ALL) are currently treated with the tyrosine kinase inhibitor (TKI) imatinib added to a chemotherapy backbone that also contains several courses of high-dose methotre...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Inge M. van der Sluis, Nikita D. van Dijk, Leiah J. Brigitha, Freya M. Steinhauer, Rob Pieters
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Elsevier 2023-12-01
coleção:	EJC Paediatric Oncology
Assuntos:	Acute lymphoblastic leukemia Imatinib High-dose methotrexate Clearance Pediatric
Acesso em linha:	http://www.sciencedirect.com/science/article/pii/S2772610X23001113
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!